Home/ Stocks/ GRCE

Grace Therapeutics, Inc. Common Stock

GRCE XNAS

$2.30 +0.04 (+1.77%) ▲ 15-min delayed

Open

$2.24

High

$2.39

Low

$2.24

Volume

80.6K

Market Cap

$38.73M

About Grace Therapeutics, Inc. Common Stock

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 5 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2026	N/A	$-7,793,000	$-0.47
FY 2026	N/A	$-7,793,000	$-0.47
Q3 2026	N/A	$-2,315,000	$-0.14
Q2 2026	N/A	$-938,000	$-0.06

Related Market News

No specific coverage for GRCE yet. Check out our latest market news or earnings calendar.

Get GRCE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Grace Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.